Pasithea Therapeutics Corp. (KTTA): who owns it and who trades it
As of Nov 16, 2026, KTTA insiders reported 3 purchases worth $178K in the last 12 months. The largest buyer was Lawrence Steinman (Director), with $100K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Pasithea Therapeutics
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, KTTA insiders reported $178K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Coastlands Capital LP | 10% owner | Purchase | 100,000 | $0.53 | $53K | Form 4 |
| Nov 28, 2025 | Lawrence Steinman | Director | Purchase | 133,333 | $0.75 | $100K | Form 4 |
| Nov 28, 2025 | Tiago Marques | CEO | Purchase | 33,333 | $0.75 | $25K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Lawrence Steinman | Director | $100K | – | Nov 28, 2025 |
| Coastlands Capital LP | 10% owner | $53K | – | Jun 17, 2026 |
| Tiago Marques | Chief Executive Officer, Director | $25K | – | Nov 28, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KTTA short interest
Low short interest. 1.2% of KTTA shares are sold short: about 1 share in 86. Over the last 12 reports the number of shares short went up 30%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 386,722 KTTA shares were sold short, 1.2% of the shares outstanding, up 121.5% from the report before. At the average daily volume of 459,545 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 386,722 | 1.16% | +121% | 459,545 | 1.0 |
| Oct 15, 2026 | 174,598 | 0.52% | +9% | 111,924 | 1.6 |
| Sep 30, 2026 | 159,831 | 0.48% | -41% | 151,144 | 1.1 |
| Sep 15, 2026 | 270,085 | 0.81% | -11% | 204,407 | 1.3 |
| Aug 31, 2026 | 303,670 | 0.91% | +20% | 218,975 | 1.4 |
| Aug 14, 2026 | 253,936 | 0.76% | +29% | 196,782 | 1.3 |
| Jul 31, 2026 | 196,600 | 0.79% | -19% | 375,837 | 1.0 |
| Jul 15, 2026 | 242,873 | 0.97% | -15% | 406,222 | 1.0 |
| Jun 30, 2026 | 287,315 | 1.15% | -8% | 2.74M | 1.0 |
| Jun 15, 2026 | 311,708 | 1.25% | +14% | 416,220 | 1.0 |
| May 29, 2026 | 274,584 | 1.10% | -8% | 469,610 | 1.0 |
| May 15, 2026 | 297,457 | 1.19% | +11% | 398,741 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Pasithea Therapeutics company events
Pasithea Therapeutics filed 9 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Sep 16, 2026.
- Sep 16, 2026AnnouncementThe warrants of Pasithea Therapeutics Corp. to purchase shares of the Company's common stock, which trade on The Nasdaq Capital Market under the symbol “KTTAW”, will expire on September 17, 2026 in accordance with their terms as provided in the Warrant Agency Agreement between the Company and… Filing
- Sep 9, 2026VoteReported shareholder vote results. Filing
- Aug 21, 2026ListingAs previously reported, on February 20, 2026, Pasithea Therapeutics Corp. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share, for the prior 30… Filing
- May 4, 2026LeadershipPasithea Therapeutics Corp. announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026. Filing
- Feb 20, 2026ListingPasithea Therapeutics Corp. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq… Filing
- Jan 28, 2026LeadershipAt a Special Meeting of Stockholders of Pasithea Therapeutics Corp., the Company’s stockholders approved an amendment to the Company’s 2023 Stock Incentive Plan, as amended, increasing the number of shares authorized for issuance under the 2023 Incentive Plan by 11,985,779 shares to 14,000,000… Filing
- Dec 15, 2025AnnouncementAs previously reported, on June 23, 2025, Pasithea Therapeutics Corp. received a notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company was not in compliance with the $1.00 minimum bid price requirement, as set forth in Nasdaq Listing Rule… Filing
- Dec 2, 2025AgreementPasithea Therapeutics Corp. agreed to sell to investors an aggregate of (i) 14,846,665 shares of common stock of the Company, par value $0.0001 per share, and (ii) 65,153,335 pre-funded warrants to purchase up to an aggregate of 65,153,335 shares of Common Stock in a best efforts public offering. Filing
- Nov 25, 2025AnnouncementThe Company issued a press release relating to positive interim Phase 1 data from its ongoing first-in-human clinical trial of PAS-004 in patients with advanced solid tumors driven by MAPK pathway alterations, including documented RAS, NF1 or RAF mutations, and in patients who have failed prior… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Pasithea Therapeutics financials
Famous investors that hold KTTA
1 of the 50 well-known investors we track reported holding KTTA in their latest 13F filing. The largest position is Ken Griffin's, worth $22.8K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 46,156 | $22.8K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named KTTA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Ameriprise Financial, Inc. | 13G/A | 4.1% |
| Nov 16, 2026 | Ameriprise Financial, Inc. | 13G/A | 4.1% |
| Nov 16, 2026 | Vivo Opportunity Fund Holdings, L.P. | 13G/A | 10.0% |
| Nov 16, 2026 | Stonepine Capital Management, LLC | 13G/A | 8.3% |
| Nov 16, 2026 | Stonepine Capital Management, LLC | 13G/A | 8.3% |
| Nov 16, 2026 | Vivo Opportunity Fund Holdings, L.P. | 13G/A | 10.0% |
| Nov 6, 2026 | Opaleye Management Inc. | 13G/A | 0.0% |
| Nov 6, 2026 | Opaleye Management Inc. | 13G/A | 0.0% |
Questions about Pasithea Therapeutics Corp. (KTTA) stock
Are KTTA insiders buying or selling?
In the last 12 months, KTTA insiders reported 3 open-market purchases worth $178K and no sales. The latest trade was on Jun 17, 2026. See every trade.
What is the short interest in KTTA?
As of Oct 30, 2026, 386,722 KTTA shares were sold short, 1.2% of the shares outstanding, up 121.5% from the report before. At the average daily volume of 459,545 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold KTTA?
1 of the 50 well-known investors we track reported KTTA in their latest 13F filing, including Ken Griffin. The largest position is worth $22.8K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.